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doi:10.1016/j.kjms.2012.02.013Abstract To assess the effect of alfuzosin (XATRAL) 10 mg once daily on sexual function in
men with moderate to severe lower urinary tract symptoms (LUTS) associated with benign
prostatic hyperplasia (BPH), patients with suggestive symptomatic BPH, an International Pros-
tate Symptom Score (IPSS) >8 (range of scores, 0e35), and sexual attempts at least once per
month were enrolled. All patients received alfuzosin 10 mg once daily for 24 weeks and were
asked to complete the IPSS test and Male Sexual Health Questionnaire at weeks 0 (baseline), 1,
4, 12, and 24. Other assessments included the International Index of Erectile Functiondfive-
item version (range of scores: 5e25), as well as onset of action and peak urinary flow rate
(Qmax). From September 2006 to May 2008, 279 patients were enrolled from nine centers in
Taiwan. At 24 weeks, alfuzosin effectively improved LUTS and quality of life, as demonstratedof Urology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College
Niaosong District, Kaohsiung 833, Taiwan.
.com.tw (P.-H. Chiang).
vier Taiwan LLC. All rights reserved.
430 T.I.S. Hwang et al.by a reduction in the IPSS total score (17.3 vs. 9.9, p < 0.001) and the IPSS bother score (3.8 vs.
2.5, p < 0.001). The majority (85%) of patients perceived an improvement of urinary symptoms
within 1 month of administration. In patients with an International Index of Erectile Func-
tiondfive-item version score of 16, alfuzosin significantly improved erectile disorder and
satisfaction subscores at each time point (p  0.02). Prolonged-release alfuzosin effectively
improved LUTS, quality of life, erectile function, and sexual satisfaction in men with BPH
and mild to severe erectile dysfunction. Alfuzosin is an effective treatment option for the
management of patients with BPH/LUTS and concomitant sexual dysfunction.
Copyright ª 2012, Elsevier Taiwan LLC. All rights reserved.Introduction
Benign prostatic hyperplasia (BPH) occurs in up to 50% of
men aged 60 years, increasing to 88% in men aged 80 years
[1]. Nearly half of these men will subsequently develop
moderate to severe lower urinary tract symptoms (LUTS)
[2]. These urinary tract symptoms can also affect sexual
function [3e5], which is considered by patients to be one of
the important aspects of the disease [6].
A clear relationship has been documented between LUTS
and sexual dysfunction [7], such as ejaculatory disorders
and erectile disorder (ED). The inconvenience caused by
these sexual disorders appears to be strongly correlated
with the severity of LUTS [5,8].
Patients with moderate to severe LUTS can be effec-
tively managed with a1 blockers. It has also been suggested
that some a1 blockers may improve sexual function in these
patients, with an appreciable improvement in overall sex
life [9]. Alfuzosin, a quinazoline derivative, is a specific,
uroselective post-synaptic a1 blocker which shows a pref-
erential tropism for the smooth muscle of the lower urinary
tract (trigone, urethra, prostate) compared with its affinity
for vascular smooth muscle [10,11]. The new prolonged-
release formulation of alfuzosin (XATRAL, 10 mg OD) has
been developed to improve patient compliance.
Earlier reports concerning symptomatic BPH and the
concomitant effect of alfuzosin on sexual function,
predominately focused on Western countries, have sug-
gested a strong correlation between improvement in LUTS
and the positive impact on sexual function [12e14]. Data on
this relationship, however, is still very limited in the Asian
population.
The Male Sexual Health Questionnaire (MSHQ) is a newly
developed questionnaire which allows a detailed and
accurate evaluation of male sexual function [8]. It has
recently been utilized to assess sexual dysfunction in
Korean and Thai patients enrolled in the Sexuality and the
Management of BPH with Alfuzosin (SAMBA) trial [15,16]. To
the best of our knowledge, the present study is the first
study to assess the effect of alfuzosin 10 mg once daily on
sexual function in Taiwanese patients, utilizing the MSHQ
and International Index of Erectile Functiondfive-item
(IIEF-5), and to confirm its efficacy and safety profile. The
results of this study would help medical communities to
better understand the impact on patient outcomes in
relation to alfuzosin treatment in BPH patients, hence,
providing information on optimal treatment of BPH in
Taiwan.Materials and methods
Patients were eligible to enroll in the study if they met
following criteria at the baseline visit. Males aged 40
years with moderate to severe LUTS suggestive of symp-
tomatic BPH were enrolled. Patients were also required to
have a total International Prostate Symptom Score (IPSS)
of 8, and be sexually active (defined as at least one of
the following activities in the past 4 weeks: intercourse,
caressing, foreplay, or masturbation). Exclusion criteria
were as follows: a known history of hepatic or renal
insufficiency, unstable angina, a concomitant life-
threatening condition, an active urinary tract infection
or acute prostatitis, prostate cancer, or a neuropathic
bladder. Patients who had undergone a minimally invasive
procedure within 6 months before enrollment, those who
had a previous transurethral resection of the prostate, or
those with planned prostate surgery or a minimally inva-
sive procedure during the study period were also
excluded. Treatment with 5a-reductase inhibitors, LUTS-
related phytotherapy or antimuscarinics for overactive
bladder or a1 blockers within 1 month before inclusion,
and receipt of any treatment for erectile dysfunction
within 1 month before inclusion were also criteria for
exclusion.
This was a phase IV, nonblind, observational, multi-
center 24-week study conducted among urologists. The
enrolled patients were instructed to take one tablet of
alfuzosin 10 mg once daily, at the end of an evening meal.
Patients were assessed at baseline and after 1, 4, 12, and
24 weeks of treatment with alfuzosin. The primary efficacy
endpoint was the mean change from baseline to week 24
or premature withdrawal in the MSHQ ejaculation score.
Secondary efficacy endpoints included the mean change
from baseline to 4 and 12 weeks in the MSHQ ejaculation
score, MSHQ erection and satisfaction subscores, and the
IIEF-5 total score. A baseline IIEF-5 score of 16 was the
cut-off sore for moderate to severe ED [17]. The mean
change from baseline to 1, 4, 12, and 24 weeks in the IPSS
total score and subscores for voiding, filling, and nocturia
symptoms and in QOL, and the percentage of patients with
an IPSS total score decrease of 3 points and 4 points
were also secondary efficacy parameters. The onset of
action based on patient perception was assessed at week
4. The mean change from baseline to 1, 4, 12, and 24
weeks in the peak urinary flow rate (Qmax) was evaluated
when Qmax was available. Safety endpoints included
adverse events, treatment-related adverse events, and
Table 1 Patient demographics at baseline (n Z 279).
Mean  SD
Age (y) 59.4  7.9
Duration of LUTS (mo) 17.0  29.0
IPSS 17.3  6.4
Voiding score 10.6  4.9
Filling score 6.7  3.4
Nocturia score 2.2  1.3
Quality of life (bother score) 3.8  1.0
MSHQ 66.9  13.4
Erection score 10.0  3.3
Erection bother score 4.0  1.1
Ejaculation score 26.7  6.5
Ejaculation bother score 4.4  1.0
Satisfaction score 21.8  4.9
IIEF-5 17.5  5.3
Erectile disorder 14.2  4.2
Satisfaction 3.2  1.3
IIEF-5 Z International Index of Erectile Functiondfive-item
version; IPSS Z International Prostate Symptom Score;
LUTS Z lower urinary tract symptoms; MSHQ Z Male Sexual
Health Questionnaire; SD Z standard deviation.
Impact of sexual function in BPH patients 431serious adverse events. The study protocol was reviewed
and approved by the institutional review board of each
participating institution, and the study was performed in
accordance with good clinical practice guidelines. Each
patient provided a written informed consent before
enrolment in the trial.
Descriptive statistics were used for the patient demo-
graphics and for the primary and secondary efficacy
endpoints. Primary efficacy analyses were conducted on
the intention-to-treat population (i.e., all patients who
received 1 dose of alfuzosin and had evaluable MSHQ and
IPSS at inclusion and provided 1 post-baseline data). All
statistical tests were two-sided with a 5% significance level.
The correlation between MSHQ and IIEF-5, and MSHQ and
IPSS was evaluated using Pearson’s correlation coefficient.
A multivariate analysis was used to calculate the change in
MSHQ ejaculation score and other subscores. The model
included age, IPSS at inclusion, region, and comorbid
conditions.Table 2 Mean change from baseline (week 0) in MSHQ subscore
Mean change Wk 4
n Mean  SD
Erection score 276 0.0  2.2
Erection bother score 278 0.2  0.9*
Ejaculation score 275 0.6  5.5
Ejaculation bother score 276 0.1  0.9
Satisfaction score 276 0.2  3.6
Total score 269 2.0  11.8*
*p < 0.05.
MSHQ Z Male Sexual Health Questionnaire; SD Z standard deviationResults
Patient demographics
A total of 279 males were enrolled from nine centers in
Taiwan between September 2006 and May 2008. Eventually,
156 patients completed the survey at week 24. Patients did
not complete the survey for the following reasons: lost to
follow-up 33.7%, lack of efficacy 13.6%, AE 10.7%, poor
compliance to study 14.8%, and others 27.2%.
Patient demographics are presented in Table 1. The
mean age was 59.4  7.9 years, the mean duration of LUTS
was 17.0  29.0 months, the mean IPSS bother score was
3.8  1.0, and the mean IIEF-5 score was 17.5  5.3.
According to the IPSS assessment, 65.2% of patients had
moderate LUTS and 34.8% had severe LUTS.Efficacy results
For the primary efficacy endpoint, the MSHQ ejaculation
score was significantly increased at 12 weeks (p Z 0.001).
However, there was no significant difference in the MSHQ
ejaculation score, erection score, and satisfaction score
between baseline and 24 weeks (Table 2). In patients with
a baseline IIEF-5 score of 16, significant increases in
erection score (p Z 0.0268), erection bother score
(p Z 0.0116), ejaculation score (p Z 0.0098), and satis-
faction score (p Z 0.0344) were observed at 12 weeks
(Table 3). There were no significant changes in the IIEF-5
total score between baseline and 24 weeks (17.5 vs.
18.1). However, in patients with a baseline IIEF-5 score of
16, there was a significant mean change in the IIEF-5 score
at weeks 4, 12, and 24 (p0.01, Table 4). There were also
significant mean changes in ED and satisfaction subscores at
each time point (p0.024, Table 4). MSHQ ejaculation and
IIEF-5 scores were positively correlated at baseline and 24
weeks (p < 0.0001).
After 24 weeks of treatment, alfuzosin 10 mg once daily
effectively improved LUTS, as evidenced by significant
improvements in the IPSS total score compared with base-
line: 17.3 versus 9.9 (p < 0.0001). A mean change of e5.1 in
IPSS total score was observed as early as week 1
(p < 0.0001). At 4, 12, and 24 weeks, significant improve-
ments were noted in all IPSS subscales including voiding,
filling, nocturia, and QOL (p < 0.0001 for all, Fig. 1). Thes at weeks 4, 12, and 24.
Mean change Wk 12 Mean change Wk 24
n Mean  SD n Mean  SD
209 0.1  2.9 156 0.2  2.9
210 0.2  1.1* 156 0.1  1.0
209 1.4  6.3* 156 0.4  6.1
209 0.2  1.1* 156 0.2  1.0
208 0.0  4.8 155 0.4  5.0
205 3.5  15.4* 151 2.1  13.3
.
Table 3 Mean change in MSHQ subscores at weeks 4, 12, and 24 in patients with baseline IIEF-5 score 16.
Mean change Wk 4 Mean change Wk 12 Mean change Wk 24
n Mean  SD n Mean  SD n Mean  SD
Erection score 101 0.0  2.0 73 0.8  3.1* 44 0.1  3.0
Erection bother score 103 0.3  1.1* 74 0.4  1.3* 44 0.3  1.1
Ejaculation score 100 0.4  7.1 73 2.7  8.6* 44 1.2  7.1
Ejaculation bother score 102 0.2  1.1 73 0.3  1.6 44 0.4  1.4
Satisfaction score 101 0.3  4.3 72 1.2  4.7* 43 0.3  5.9
Total score 99 2.3  13.4 72 8.3  18.8* 42 5.9  15.0*
*p < 0.05.
IIEF-5 Z International Index of Erectile Functiondfive-item version; MSHQ Z Male Sexual Health Questionnaire; SD Z standard
deviation.
432 T.I.S. Hwang et al.majority of patients (74.3%) had a decrease of 3 points in
the IPSS total score at week 24. A small proportion of
patients (7.9%) had a reduction of 4 points at week 24.
There was a negative correlation between MSHQ and IPSS
total score at baseline and 24 weeks (p Z 0.0002). There
was a significant improvement in peak urinary flow: mean
Qmax at baseline versus week 24 was 13.7 versus 15.4
(p Z 0.008).
Safety results
All patients were evaluable for the safety analysis.
Approximately one-third of patients (30.7%) reported an
adverse event with alfuzosin. The most common adverse
events were dizziness (11.5%), hypertension (4.3%), palpi-
tation (3.6%), and upper respiratory tract infection (3.6%).
Overall, 28.2% of adverse events were treatment-related.
Treatment with alfuzosin was discontinued in four out of
five patients experiencing palpitations and in five out of 16
patients experiencing dizziness. There were no significant
changes in blood pressure or heart rate.
Discussion
The efficacy of a1 blockers in participants with LUTS
suggestive of BPH has been well demonstrated by numerous
placebo-controlled studies. As a result of this, guidelines on
BPH currently recommend a1 blockers as a first-line medical
treatment in this indication [18,19]. In general, a1 blockers
as a class have similar efficacy in the treatment of LUTS/
BPH; however, these agents have varying tolerabilityTable 4 Mean change in IIEF-5 subscores at weeks 4, 12, and 2
Mean change Wk 4
n Mean  SD
Total score 91 1.3  4.5*
Erectile disorder 91 1.0  3.7*
Satisfaction 91 0.2  1.0*
*p < 0.05.
IIEF-5 Z International Index of Erectile Functiondfive-item version;
ation.profiles with regard to adverse vasodilatory effects and
sexual dysfunction [20]. For example, since tamsulosin and
alfuzosin are uroselective and are associated with fewer
vascular-related adverse events, these agents may have
particular utility in older males with cardiovascular
comorbidities [20,21]. However, due to a higher incidence
of ejaculatory dysfunction, tamsulosin and silodosin may
not be the treatment of choice in younger sexually active
males [20e22].
The efficacy of alfuzosin in alleviating symptoms and in
improving maximum flow rate has been documented in
well-designed controlled and open studies [23e25]. In a 3-
month, double-blind, randomized, placebo-controlled
study, prolonged-release alfuzosin 10 mg once daily signif-
icantly improved urinary symptoms and peak flow rate
(Qmax) with a proven 24-hour efficacy [26]. The efficacy of
this formulation of alfuzosin administered 10 mg once daily
was confirmed in the current study. After 24 weeks, alfu-
zosin effectively improved LUTS and peak flow rate, and
significant improvements were observed with regard to
QOL. Importantly, alfuzosin had a rapid onset of action,
with the majority (85%) of patients reporting an improve-
ment in urinary symptoms within 1 month of
administration.
Evidence indicates that there is a high prevalence of
ejaculatory disorders and ED, particularly in men with
moderate or severe LUTS [26]. Data from the US BPH
Registry (n Z 3084) confirm a significant association
between LUTS and erectile dysfunction (p < 0.0001) [26].
Despite the lack of agreement on the underlying mecha-
nism involved, several hypotheses have been advanced to
account for this association. In particular, the role of4 in patients with baseline IIEF-5 score 16.
Mean change Wk 12 Mean change Wk 24
n Mean  SD n Mean  SD
67 2.7  5.3* 44 2.6  5.8*
67 2.1  4.4* 44 2.0  4.8*
67 0.6  1.3* 44 0.7  1.5*
MSHQ Z Male Sexual Health Questionnaire; SD Z standard devi-
Figure 1. International Prostate Symptom Score (IPSS), total and sub scores over 24 weeks of treatment with alfuzosin 10 mg
once daily. *p<0.0001 vs. baseline.
Impact of sexual function in BPH patients 433autonomic hyperactivity has been proposed as a common
link between LUTS, ED, and hypertension in aging men
[27,28]. Other explanations include the potential role of
decreased nitric oxide production in the prostate and penis
smooth muscle, or pelvic atherosclerosis and endothelial
dysfunction. In vitro data from cavernosal tissues obtained
from patients undergoing penile surgery (nZ 10) show that
beneficial effects on cavernosal smooth muscle relaxation
are observed with alfuzosin alone or in combination with
tadalafil in patients whose ED is not sufficiently controlled
by tadalafil monotherapy [29]. This study also demon-
strated that the combination of alfuzosin plus tadalafil is
more effective than either agent administered as mono-
therapy for relaxing adrenergic tone or enhancing nitrergic
relaxation of the human corpus cavernosum, suggesting
that this combination may be useful in patients with ED who
do not show sufficient improvement following the use of
phosphodiesterase type 5 inhibitors [29]. The use of
a blockers is associated with a decreased risk of sexual
dysfunction in patients with LUTS/BPH, although there is
evidence to suggest that this reduction in the risk of erec-
tile dysfunction and low libido is only significant in males
who have an improvement in LUTS [30].
In the current study, alfuzosin significantly improved ED
and satisfaction as assessed by the MSHQ ejaculation and
the IIEF-5 subscores, in patients with mild to severe erectile
dysfunction. Improvements in sexual function as deter-
mined by the MSHQ were significantly correlated with those
recorded by the IIEF-5. In patients with a baseline IIEF-5
score of 16, alfuzosin significantly improved erectile
function, as assessed by IIEF-5 and MSHQ, indicating that
alfuzosin may be particularly useful in patients with mild to
severe ED. The improvement in erectile function remained
significant when the cut-off score of IIEF-5  11 (moderate
to severe ED) and 16 (mild to severe ED) was used. The
benefits of alfuzosin 10 mg once daily on sexual function
have also been confirmed in a number of other studies
[12,15,31,32]. The improvement in sexual function was
particularly evident in men with severe LUTS or a severe
bother score at baseline [12].
The results of the current study are in line with those of
the similarly designed 24-week SAMBA trial, conducted in148 Korean patients aged 50 years with BPH [15]. Patients
enrolled in these two studies had similar baseline charac-
teristics: mean age (59.4 vs. 57.8 years in the Korean SAMBA
trial), total IPSS (17.3 vs. 17.4, respectively), and bother
score (3.8 vs. 3.9, respectively) [15]. In both studies, an
improvement in urinary symptoms with alfuzosin 10 mg
once daily was paralleled by significant improvements in
ejaculatory function. Furthermore, these improvements, as
measured by the MSHQ, were correlated with IIEF-5. While
the onset of action of alfuzosin was not evaluated in Korean
patients [15], the current study demonstrated significant
improvements in IPSS total scores following 1 week of
treatment.
In this study, the MSHQ ejaculation score was signifi-
cantly improved at week 12, but the significant improve-
ment was not observed at week 24. A major limitation of
the current study was the high incompletion rate of MSHQ
questionnaire (44%) at week 24, which might have
contributed to the lack of a significant difference observed
in the primary endpoint. Nevertheless, overall our results
are in line with those of the similarly designed SAMBA trial,
in which 83% of patients were evaluable in the final analysis
[15].
In males with LUTS/BPH and mild to severe erectile
dysfunction, prolonged-release alfuzosin significantly
improved erectile function and satisfaction. Alfuzosin also
significantly improved LUTS, and improved QOL in these
patients. The current study demonstrates that alfuzosin is
an effective treatment option in the management of
patients with BPH/LUTS and concomitant sexual
dysfunction.
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